



## **ESIU/EAU-symposium in Oslo 15.Dec. 2017**

**Venue: Auditoriet, 1.etg. Kreftsenteret, Ullevål Hospital**

**Time: Friday 15.Dec 11:00-15:40**

### **Fast facts in urogenital infections and prostate cancer**

The first GPIU symposium in Norway

**Chairs: Florian Wagenlehner and Truls E. Bjerklund Johansen**

**Opening by Bjørn Guldvog, MD, PhD**

**Chief Medical Officer (CMO) of Norway, the Norwegian Directorate of Health**

**The symposium is open to all interested health personnel and the general public. There is no registration fee. Symposium seats and lunch tickets in the "Søsterhjemmet" may be reserved at [sobbia.livingtextbook@gmail.com](mailto:sobbia.livingtextbook@gmail.com)**

The symposium is organized by the European Association of Urology in collaboration with the Norwegian Institute of Urology and the Russian-Norwegian Collaborative Urology Group and sponsored by the University of Oslo, The European Association of Urology and several pharmaceutical companies

ESIU: European Section of Infections in Urology   EAU: European Association of Urology   GPIU: Global Prevalence study of Infections in Urology



11:00-11:05	<p>OPENING            Bjørn Guldvog, MD, PhD            Chief Medical Officer (CMO) of Norway            The Norwegian Directorate of Health</p>		
Time slots	Speaker	Affiliation	Title
11:05-11:20	Dominique Monnet	ECDC, Stockholm, Sweden	Multidrug-resistant bacteria in returning international travelers: implications for prophylaxis and treatment of infections in urology
11:20-11:35	Tommaso Cai	Trento, Italy	Infective complications and recommended prophylaxis in prostate biopsies - a global perspective based on GPIU data.
11:35-11:50	Zafer Tandogdu	Newcastle, UK and Oslo, Norway	Urosepsis, the most feared infective complication. What is it really? Interim data from the GPIU-Serpens study
11:50-12:05	Knut Kvernebo	Oslo, Norway	Can we foresee the development of septic shock by measurement of skin microcirculation?
12:05-12.20	Vladimir Mouraviev	Florida, US	Can we improve prophylaxis and treatment of UTI by means of urine microbiome analysis?
12:20-12.35	Erik Rud	Oslo, Norway	Is it possible that MR can provide us with histological diagnosis and that patients can thus avoid prostate biopsy?
12:35-12-50	Florian Wagenlehner	Giessen, Germany	What is the role of infection and inflammation in prostate cancer? New insight based on microbiome studies
12:50-13:30	LUNCH		



13:30-13:45	Bjørn Wullt	Lund, Sweden	The immune response in UTI
13:45-14:00	Reino Heikkilä	Oslo, Norway	Immune check point inhibitors and how it translates to treatment of prostate cancer
14:00-14:15	Tamara Perepanova	Moscow, Russia	Antimicrobial resistance and the role of bacteriophage treatment in Russia
14:15-14:30	Oleg Apolikhin	Moscow, Russia	P4 medicine, a new paradigm in the prevention of UTI (predictive, preventive, personalized, and participatory)
14:30-14.45	Ekaterina Kulchavenya	Novosibirsk, Russia	Occurrence, resistance and treatment of urogenital TB in Russia
14:45-15:00	Bela Koves	Budapest, Hungary	Evidence based management of catheter-associated urinary tract infections
15:00-15.15	Zafer Tandogdu	Newcastle, UK and Oslo, Norway	Can we foresee antimicrobial resistance by means of mathematical modelling?
15:15-15:25	Kurt Naber	Munich, Germany	Revival of old antibiotics to cope with antimicrobial resistance
15:25-15:35	Florian Wagenlehner	Giessen, Germany	Novel antibiotics in the treatment of urinary tract infections
15:35-15:40	CLOSE Truls E. Bjerklund Johansen, Oslo, Norway		



**Truls E. Bjerklund Johansen**  
Professor dr.med., overlege  
Urologisk avdeling  
Oslo Universitetssykehus  
Co-chair ESIU/EAU



**Florian Wagenlehner**  
Professor dr.med., avdelingsleder  
Avdeling for urologi, barneurologi og andrologi  
Universitetssykehuset i Giessen, Tyskland  
Chair ESIU/EAU